Philip B. Adamson, M.D., MSc, FACC is divisional vice president, Global Clinical Affairs and medical director at Abbott. He is responsible for global development of Abbott's heart failure programs, including cardiac resynchronization therapy, the CardioMEMS HF™ system and our Mechanical Circulatory Support portfolio, including the HeartMate 3™ heart pump.
Dr. Adamson joined Abbott (formerly St. Jude Medical) in 2015. His clinical interests focus on development of more efficient and effective disease management systems for patients with chronic heart failure, specifically focusing on remote monitoring of physiologic signals from implanted devices.
Prior to joining Abbott, Dr. Adamson helped developed a novel cardiology training curriculum designed to provide skills in device implantation and management along with expertise in outpatient multidisciplinary disease management program development. He has served as the principal investigator on the steering committees of several large randomized clinical trials. In this capacity he was the co-principal investigator of the CHAMPION Trial, which demonstrated the efficacy and safety of the CardioMEMS HF System, leading to FDA approval of the system in 2014.
Dr. Adamson received his M.D. and master's of science in cardiovascular physiology and heart failure from the University of Oklahoma Health Sciences Center. He joined the faculty at the University of Oklahoma as a Warren Foundation Investigator and received funding to develop a novel model of ischemic heart failure that served to investigate the autonomic mechanisms of sudden cardiac death. Dr. Adamson remained on the faculty for more than 20 years. He holds a bachelor's of science with dual majors in accounting and physiology from the University of Central Oklahoma.
Dr. Adamson has recently been elected to be a Fellow of the Royal College of Physicians in Edinburgh (UK). He also remains an Adjunct Associate Professor of Physiology at the University of Oklahoma Health Sciences Center.